trans/cis-3,4,5-trimethoxybenzoic acid 4-(4-hydroxycyclohexylamino)cyclohexyl ester | 929548-63-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: trans/cis-3,4,5-trimethoxybenzoic acid 4-(4-hydroxycyclohexylamino)cyclohexyl ester
• CAS: 929548-63-0
• 化学式: C₂₂H₃₃NO₆
• 分子量: 407.507
• InChiKey: HBWPFUNBGDLPEW-DCIVCYTQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.07
• 重原子数：
  29.0
• 可旋转键数：
  7.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  86.25
• 氢给体数：
  2.0
• 氢受体数：
  7.0

反应信息

• 作为反应物：
  描述：

  trans/cis-3,4,5-trimethoxybenzoic acid 4-(4-hydroxycyclohexylamino)cyclohexyl ester 在 甲酸 作用下， 以 乙醇 、 氯仿 为溶剂， 反应 10.0h， 生成 trans/cis-3,4,5-trimethoxybenzoic acid 4-(methyl{4-[3-(3,4,5-trimethoxyphenyl)acryloyloxy]cyclohexyl}amino)cyclohexyl ester
  参考文献：
  名称：

  Isomeric N,N-Bis(cyclohexanol)amine Aryl Esters:  The Discovery of a New Class of Highly Potent P-Glycoprotein (Pgp)-dependent Multidrug Resistance (MDR) Inhibitors

  摘要：

  A new series of P-glycoprotein (Pgp)-dependent multidrug resistance (MDR) inhibitors having a N,N-bis(cyclohexanol)amine scaffold have been designed, following the frozen analog approach. With respect to the parent flexible molecules, the new compounds show improved potency and efficacy. Among them, compound 1d, on anthracycline-resistant erythroleukemia K562 cells, is able to completely reverse Pgp-dependent MDR at low nanomolar concentration.

  DOI：

  10.1021/jm0614432
• 作为产物：
  描述：

  3,4,5-三甲氧基苯甲酸 在 titanium(IV) isopropylate 、 氯化亚砜 、 sodium cyanoborohydride 作用下， 以 乙醇 、 氯仿 、 苯 为溶剂， 反应 35.0h， 生成 trans/cis-3,4,5-trimethoxybenzoic acid 4-(4-hydroxycyclohexylamino)cyclohexyl ester
  参考文献：
  名称：

  Isomeric N,N-Bis(cyclohexanol)amine Aryl Esters:  The Discovery of a New Class of Highly Potent P-Glycoprotein (Pgp)-dependent Multidrug Resistance (MDR) Inhibitors

  摘要：

  A new series of P-glycoprotein (Pgp)-dependent multidrug resistance (MDR) inhibitors having a N,N-bis(cyclohexanol)amine scaffold have been designed, following the frozen analog approach. With respect to the parent flexible molecules, the new compounds show improved potency and efficacy. Among them, compound 1d, on anthracycline-resistant erythroleukemia K562 cells, is able to completely reverse Pgp-dependent MDR at low nanomolar concentration.

  DOI：

  10.1021/jm0614432